FPA150 in Patients With Advanced Solid Tumors

Summary

This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.

Timeline

Start

2018-03-27

Primary completion

2021-04-21

Completion

2021-04-21

Outcome

Outcome not reported

Stopped: “The Sponsor terminated the study for reasons unrelated to safety.”

Drugs

Indications